Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial
Abstract
Background: Effective anti‐inflammatory treatments for hidradenitis suppurativa (HS) are limited. Objective: To evaluate the efficacy and short‐term safety of apremilast in patients with moderate HS. Methods: A total of 20 patients with moderate HS were randomized in a 3:1 ratio to receive blinded treatment with apremilast, 30 mg twice daily, or placebo for 16 weeks. The primary outcome was the Hidradenitis Suppurativa Clinical Response at week 16. Linear mixed effects modeling (analysis of covariance) was used to assess secondary clinical outcomes between treatment groups. Results: The HS clinical response was met in 8 of 15 patients in the apremilast group (53.3%) and none of 5 patients in the placebo group (0%) (P = .055) at week 16. Moreover, the apremilast‐treated patients showed a significantly lower abscess and nodule count (mean difference, –2.6; 95% confidence interval, –6.0 to –0.9; P = .011), NRS for pain (mean difference, –2.7; 95% –4.5 to –0.9; P = .009), and itch (mean difference, –2.8; 95% confidence interval, –5.0 to –0.6; P = .015) over 16 weeks compared with the placebo‐treated patients. There was no significant difference in the Dermatology Life Quality Index over time between the 2 treatment groups (mean difference, –3.4; 95% confidence interval, –9.0 to 2.3; P = .230). The most frequently reported adverse events in the apremilast‐treated patients were mild‐to‐moderate headache and gastrointestinal symptoms, which did not result in dropouts. Limitations:…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
- Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.